CD BioGlyco can customize one-stop services for glycoengineered antibodies according to customers' R&D or cGMP production needs. We have confidence to be your essential research assistant in the field of glycobiology.
Monoclonal antibodies (mAbs) are currently the largest and fastest-growing category of biopharmaceuticals. Since 1984, more than 60 mAbs and fusion molecules has been approvedfor use in more than 30 cancers, autoimmune and cardiovascular diseases. It is estimated that by 2024, the global market value of mAbs will reach 138.6 billion dollars.
The clinical efficacy and safety of mAbs are affected by their glycosylation structure and composition. Glycosyl distribution is usually heterogeneous, depends largely on the manufacturing process, and is therefore susceptible to changes in cell culture conditions. Therefore, it is considered a key quality attribute of mAbs. Great efforts have been made in mammalian and non-mammalian cells to control the glycosylation of mAbs. However, it is still a challenge to obtain a specific glycoform that is completely homogeneous.
The latest innovations in chemoenzymatic glycoengineering technology will allow the production of mAbs with well-defined and uniform Fc glycoforms, thereby giving them the desired biological properties. This method has significant advantages, such as enhanced Fc effector function, improved safety, higher batch-to-batch consistency, reduced immunogenicity, and can be expressed economically. Overall, producing mAbs with the innovative glycoengineering technology will bring tangible benefits to patients and manufacturers.
Fig 1. Schematic structure of common IgG antibodies (Wang, L.; et al. 2019)
Mammalian host systems are the preferred expression platform because they can maximize the post-translational processing and functional activity of proteins.
Chemoenzymatic glycoengineering refers to the in vitro remodeling of glycans using enzymes such as endoglycosidase and sugar synthase.
The synthesis laboratory at CD BioGlyco uses the most advanced click technology to provide antibody remodeled by glycoforms for customers.
CD BioGlyco aims to provide customers with unparalleled support services for antibody digestion. We have the confidence to be your essential research assistant.
With our advanced glycoengineering platform, CD BioGlyco provides customers with strong support for antibody deglycosylation.
CD BioGlyco has experienced scientists and the most advanced technology platforms, which can provide customers with tailor-made services in the design and expression of glycoengineered antibodies, and our powerful analysis platform will provide a guarantee for the final products.
If you are interested in our services, please contact us for more detailed information.